Toggle Summary |
Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes
|
View HTML
|
Toggle Summary |
Onconova Announces Presentation of Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer at AACR 2013 Annual Meeting
Oral Rigosertib Progresses to Phase 2 Clinical Trial in Squamous Cell Head and Neck Cancers
|
View HTML
|
Toggle Summary |
Onconova Appoints Ajay Bansal as Chief Financial Officer
|
View HTML
|
Toggle Summary |
GVK Biosciences and Onconova Therapeutics Establish Novel Joint Development Partnership to Advance New Drugs for Cancer
|
View HTML
|
Toggle Summary |
Onconova Presents Positive Clinical Results for Rigosertib at ASH Meeting
Three Trials Demonstrate Safety and Tolerability in Hematological Malignancies
|
View HTML
|
Toggle Summary |
Onconova Appoints Dr. Thomas J. McKearn as President, Research and Development
|
View HTML
|
Toggle Summary |
Onconova Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD®
|
View HTML
|
Toggle Summary |
Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib
Rigosertib in Late-Stage Studies for MDS and Pancreatic Cancer
|
View HTML
|
Toggle Summary |
Onconova Presents Clinical Trial Data for Oral Rigosertib at ASCO Annual Meeting
Two Clinical Trials Assessed Oral Safety and Bioavailability
|
View HTML
|
Toggle Summary |
Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes
Complete Phase I Data to be Reported at ASCO 2012 Annual Meeting
|
View HTML
|